dailyai.report

Biologic medicines rely on engineered proteins, a process historically plagued by high costs and frequent failure. New AI tools now predict protein structures and interactions with higher precision. MIT Tech Review highlights how these models reduce the trial-and-error cycle. This shift allows researchers to identify viable drug candidates faster, cutting years from traditional development timelines.